Half-year report · Q2
2385.TEDINET S100V7YR
Period2024-07-01 → 2024-12-31
Filed2025-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.7bn | 2024-07-01 → 2024-12-31 | Cons. | Net sales |
| Revenue | ¥5.2bn | 2023-07-01 → 2024-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.8bn | 2023-07-01 → 2023-12-31 | Cons. | Net sales |
| Operating income | −¥203m | 2024-07-01 → 2024-12-31 | Cons. | Operating income |
| Operating income | −¥455m | 2023-07-01 → 2023-12-31 | Cons. | Operating income |
| Ordinary income | −¥198m | 2024-07-01 → 2024-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥566m | 2023-07-01 → 2024-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥449m | 2023-07-01 → 2023-12-31 | Cons. | Ordinary income |
| Profit before tax | −¥212m | 2024-07-01 → 2024-12-31 | Cons. | Income before income taxes |
| Profit before tax | −¥449m | 2023-07-01 → 2023-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥222m | 2024-07-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥662m | 2023-07-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥488m | 2023-07-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥222m | 2024-07-01 → 2024-12-31 | Cons. | Profit loss |
| Net income | −¥489m | 2023-07-01 → 2023-12-31 | Cons. | Profit loss |
| Total assets | ¥6.6bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥6.9bn | at 2024-06-30 | Cons. | Assets |
| Total assets | ¥7.1bn | at 2023-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥557m | at 2024-12-31 | Cons. | Liabilities |
| Total liabilities | ¥697m | at 2024-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥6.0bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥6.2bn | at 2024-06-30 | Cons. | Net assets |
| Net assets / equity | ¥6.4bn | at 2023-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.6bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.8bn | at 2024-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.6bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.8bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.9bn | at 2023-06-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥98m | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥881m | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥967m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥324m | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥14m | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥10m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥172,000 | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥261m | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥260m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-8.5 | 2024-07-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-25.32 | 2023-07-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-18.65 | 2023-07-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 91.3% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.7% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.9% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 50
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-07-01 → 2024-12-31 | −¥14m |
| Reconciling Itemsreconciling | revenue external | 2024-07-01 → 2024-12-31 | ¥900,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-07-01 → 2024-12-31 | −¥15m |
| Reconciling Itemsreconciling | segment profit | 2024-07-01 → 2024-12-31 | −¥159m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥152m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥152m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥19m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥751m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥751m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥25m |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥1.2bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥1.2bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥4m |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | segment profit | 2024-07-01 → 2024-12-31 | −¥132m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥183m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥173m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥11m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥3m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥393m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥393m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥39m |
| —segment total | revenue | 2024-07-01 → 2024-12-31 | ¥2.7bn |
| —segment total | revenue external | 2024-07-01 → 2024-12-31 | ¥2.7bn |
| —segment total | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥15m |
| —segment total | segment profit | 2024-07-01 → 2024-12-31 | −¥45m |
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-12-31 | −¥10m |
| Reconciling Itemsreconciling | revenue external | 2023-07-01 → 2023-12-31 | ¥900,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-12-31 | −¥11m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-12-31 | −¥156m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥176m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥176m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥1m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥779m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥779m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | segment profit | 2023-07-01 → 2023-12-31 | −¥72m |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥3m |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | segment profit | 2023-07-01 → 2023-12-31 | −¥270m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥165m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥157m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥8m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | segment profit | 2023-07-01 → 2023-12-31 | −¥701,000 |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥337m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥337m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥43m |
| —segment total | revenue | 2023-07-01 → 2023-12-31 | ¥2.9bn |
| —segment total | revenue external | 2023-07-01 → 2023-12-31 | ¥2.8bn |
| —segment total | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥11m |
| —segment total | segment profit | 2023-07-01 → 2023-12-31 | −¥299m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 447
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments for guarantee deposits inv cf | Prior1YTDDuration | － | JPY |
| Payments for guarantee deposits inv cf | CurrentYTDDuration | -310000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -9933000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -324274000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -131230000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -172000 | JPY |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | Prior1YTDDuration | -129262000 | JPY |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -260492000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -172000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -1237203000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -226843000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 5945854000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 4790024000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 4708650000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 4563180000 | JPY |
| Advertising expenses sga | Prior1YTDDuration | 538949000 | JPY |
| Advertising expenses sga | CurrentYTDDuration | 420850000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 16248000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 20990000 | JPY |
| Depreciation sga | Prior1YTDDuration | 10605000 | JPY |
| Depreciation sga | CurrentYTDDuration | 4823000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 10280000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 11687000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | -31000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | － | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 175540000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | 337277000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 778904000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 1390869000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 156894000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 2839485000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | 900000 | JPY |
| Revenues from external customers | Prior1YTDDuration | 2840385000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 2868000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 7999000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 10868000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -10868000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 175540000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | 337277000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 778904000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 1393737000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 164893000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 2850353000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -9968000 | JPY |
| Net sales | Prior1YTDDuration | 2840385000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |